Analysts: GM Will Improve Throughout 2013 and 3 More Research Notes to Check Out

General Motors Co. (NYSE:GM): RBC Capital increased its target on GM to $45 from $41, as the firm believes the company reported solid second-quarter results. RBC now has more confidence that the company’s results will improve meaningfully in the second half of the year, and it keeps an Outperform rating.


Boston Scientific (NYSE:BSX): RBC Capital expects Boston Scientific’s shares to be boosted by new product launches and continued cost cutting, and the firm keeps an Outperform rating on the shares.


Celgene (NASDAQ:CELG): Cantor has raised its price target on Celgene to $156 from $142 after the company reported stronger-than-expected results. The firm keeps a Buy rating on the shares.


Whiting Petroleum (NYSE:WLL): Brean Capital has raised its price target on Whiting Petroleum to $75 from $67 following second-quarter results and expects improving well results from the company’s Bakken and Redtail Niobrara plays to drive share price appreciation. It has a Buy rating on the stock.


Don’t Miss: 5 Premium Brands Making a Killing in the U.S. Car Market.